CAROLYN BRITTEN was named director of the Hematology/Oncology Division at the Medical University of South Carolina. She will continue her role as associate director for clinical investigations at the MUSC Hollings Cancer Center.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
